AIM shares surge 61.14% premarket after positive Phase 2 pancreatic cancer data shows 19.7-month survival, no significant toxicity, and orphan drug designations.

AIM ImmunoTech surged 61.14% in premarket trading following positive interim Phase 2 data for Ampligen combined with AstraZeneca’s Imfinzi in metastatic pancreatic cancer. The trial reported a 19.7-month median survival (vs. 8.6 months with standard care), no significant toxicity, and enhanced quality of life, supported by ongoing enrollment of 18 of 25 planned patients. The data, highlighted in a year-end update, underscores Ampligen’s potential as a first-in-class therapy with orphan drug designations and patent protection through 2039. CEO Thomas Equels emphasized the treatment’s novel immune-activation mechanism and market exclusivity, positioning it as a high-impact candidate for Phase 3 trials. These developments, coupled with strategic collaborations and intellectual property strength, drove immediate investor optimism, aligning with the stock’s sharp premarket rise.